Stockscreener 앱 받기
2.18
28.24%
0.48
전일 마감가:
$1.70
열려 있는:
$2.05
하루 거래량:
88.79M
Relative Volume:
59.07
시가총액:
$33.03M
수익:
$2.79M
순이익/손실:
$9.17M
주가수익비율:
1.5924
EPS:
1.369
순현금흐름:
$-20.77M
1주 성능:
+46.31%
1개월 성능:
+39.74%
6개월 성능:
+11.79%
1년 성능:
+55.71%
1일 변동 폭
$1.79
$2.3999
1주일 범위
$1.45
$2.3999
52주 변동 폭
$0.97
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
명칭
Traws Pharma Inc
전화
267-759-3680
주소
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.18 | 33.03M | 2.79M | 9.17M | -20.77M | 1.369 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | H.C. Wainwright | Buy |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-18 | 개시 | Guggenheim | Buy |
| 2018-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-09 | 개시 | H.C. Wainwright | Buy |
| 2017-04-27 | 개시 | Laidlaw | Buy |
| 2015-07-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 개시 | H.C. Wainwright | Buy |
모두보기
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Traws Pharma Soars As Hantavirus Antiviral Plan Sparks Rally - timothysykes.com
Traws Pharma (NASDAQ: TRAW) registers 35.9M resale shares - Stock Titan
Traws Pharma to Advance Potential Hantavirus Treatment Clinical Candidates - Contract Pharma
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths - TechStock²
Traws Pops on Hantavirus Research - Baystreet.ca
Traws Pharma Expands Antiviral Program to Target Hantavirus Infections; Shares Up Pre-Bell - Moomoo
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak - Benzinga
TRAW Stock Jumps As Traders Zero In On Momentum And Cash Runway - StocksToTrade
TRAW Stock Pops On Volatile Run As Traders Eye Breakout - timothysykes.com
Traws Pharma to Advance Clinical Candidates for Hantavirus Infections - geneonline.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Traws Pharma To Advance Potential Clinical Candidates For The Treatment Of Hantavirus Infections - TradingView
Traws Pharma to develop hantavirus treatment candidates By Investing.com - Investing.com Australia
Traws Pharma to develop hantavirus treatment candidates - Investing.com
Traws Pharma Advances Development of Clinical Candidates for Hantavirus Treatment - Quiver Quantitative
No approved hantavirus treatment; Traws plans drug push - Stock Titan
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections - ChartMill
Number of shareholders of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Newtown-based Traws Pharma shares full-year results, clinical progress - MSN
OrbiMed (NASDAQ: TRAW) details 11.9% Traws Pharma stake and warrants - Stock Titan
TRAW (Traws Pharma) delivers stunning Q4 2025 EPS beat, shares rise 1.34% on upbeat investor reception.High Interest Stocks - newser.com
Traws Pharma posts 150.5% EPS surprise turning profitable vs loss estimatesElite Trading Signals - Newser
Traws Pharma, Inc. 2025 Executive Compensation, Governance, and Board of Directors Overview - Minichart
Traws Pharma (NASDAQ: TRAW) 10-K/A details board, pay and ownership - Stock Titan
Insider Stock Purchases: April 29, 2026 - Quiver Quantitative
Traws Pharma Stock (TRAW) Opinions on Insider Purchase - Quiver Quantitative
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott By Investing.com - Investing.com South Africa
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott - Investing.com UK
TRAW Traws Pharma delivers massive Q4 2025 earnings beat, shares gain 7.44 percent on positive investor sentiment.Management Guidance - Newser
TRAW | Traws Pharma, Inc. Common Insider Trading - Quiver Quantitative
OrbiMed acquires $998,207 in Traws Pharma common stock By Investing.com - Investing.com Australia
OrbiMed acquires $998,207 in Traws Pharma common stock - Investing.com
OrbiMed (NASDAQ: TRAW) adds Traw Pharma stock and warrant stake - Stock Titan
TRAW - Finviz
Traws Pharma (TRAW) price target decreased by 24.14% to 5.61 - MSN
Traws Pharma, Inc. (TRAW) forms 'hammer chart pattern': Time for bottom fishing? - MSN
Newtown-Based Traws Pharma Shares Full-Year Results, Clinical Progress - BUCKSCO.Today
Traws Pharma Inc. notches 43.1% EPS beat on narrower lossCommunity Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Traws Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Traws Pharma (TRAW) Sector Trends | Traws Pharma Inc. notches 43.1% EPS beat on narrower lossOptions Activity - Cổng thông tin điện tử Tỉnh Sơn La
Traws Pharma Reports 2025 Results, Secures Up to $60M Financing - MyChesCo
Traws Pharma (TRAW) Stock Breakdown Level (Smart Money Flows) 2026-04-20Viral Momentum Stocks - UBND thành phố Hải Phòng
Traws Pharma Secures Up to $60 Million in Private Placement Financing - Global Legal Chronicle
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Cash per share of Traws Pharma, Inc. – MUN:0T20 - TradingView
Is Traws Pharma (TRAW) a Possible Value Trap After FY2025 Result - GuruFocus
TRAW Stock Chart | TRAWS PHARMA INC (NASDAQ:TRAW) - ChartMill
Traws outlines $60M financing while targeting flu challenge study this summer and runway into Q1 2027 - MSN
Earnings call transcript: Traws Pharma Q4 2025 shows strategic shift boosts revenue By Investing.com - Investing.com South Africa
Earnings call transcript: Traws Pharma Q4 2025 shows strategic shift boosts revenue - Investing.com
Traws Pharma, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Traws Pharma Inc (TRAW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
11.97%
3.48%
자본화:
|
볼륨(24시간):